4D Molecular Therapeutics, Inc. 8-K

What Happened
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K on June 22, 2026 reporting the results of its virtual 2026 Annual Meeting held June 17, 2026. On the record date (April 20, 2026) there were 52,274,735 shares outstanding and 44,038,022 shares were voted. Class III director nominees Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello were elected to serve until the 2029 Annual Meeting. PricewaterhouseCoopers LLP was ratified as the company’s independent registered public accounting firm for fiscal 2026. The advisory (non‑binding) vote on executive compensation (say‑on‑pay) was approved by a majority of votes cast.

Key Details

• Meeting date and filing: Annual Meeting held June 17, 2026; Form 8-K filed June 22, 2026.
• Shares: 52,274,735 shares outstanding (record date April 20, 2026); 44,038,022 shares voted.
• Director elections (votes recorded; broker non‑votes = 6,964,792):
  • Nancy Miller‑Rich — For: 35,880,028; Withheld: 1,193,202.
  • John F. Milligan, Ph.D. — For: 35,778,121; Withheld: 1,295,109.
  • Shawn Cline Tomasello, MBA — For: 30,508,706; Withheld: 6,564,524.
• Auditor ratification: PwC ratified — For: 43,900,362; Against: 55,763; Abstain: 81,897.
• Say‑on‑pay (advisory): For: 36,065,437; Against: 940,414; Abstain: 67,379; Broker non‑votes: 6,964,792.

Why It Matters
Board composition and governance votes affect company oversight and investor confidence. The re‑election of the Class III directors determines leadership through the 2029 meeting, ratification of PwC confirms continuity of the external auditor for fiscal 2026, and the strong advisory support for executive compensation signals shareholder approval of the company’s pay practices (though the vote is non‑binding). Broker non‑votes show a portion of shares did not vote on certain matters, which can be relevant for assessing shareholder engagement.